New blood test for faster sepsis diagnosis in children
Part of Genetic & congenital, Infections clinical trials.
This trial tests a new, faster way to find bacteria in the blood of children with suspected sepsis. It uses a molecular test that may give results sooner than standard cultures, helping doctors treat infections more quickly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is having a blood culture done as part of their regular care, or had one in the last 3 days.
- Your child is not diagnosed with an autoimmune disease, hemophagocytic syndrome, or a severe viral infection causing whole-body inflammation.
- If your child is a newborn, they do not have a confirmed congenital infection (like toxoplasmosis, rubella, or herpes).
- There is no other clear, non-infection cause for your child's illness.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to find new ways to quickly diagnose sepsis (a severe response to infection) in patients arriving at the emergency room. If successful, these new tests could help doctors start treatment faster.
This trial is testing whether a new, highly sensitive blood test (droplet digital PCR) combined with genetic analysis can help doctors predict sepsis earlier in emergency room patients. This could lead to faster treatment and better outcomes.
This study tests a new blood test (Microbio InfectID-BSI) to see how well it detects bacteria and yeast in patients with a possible bloodstream infection. If you are already having a blood culture done, the study will collect extra blood samples at the same time to compare the new test's results.
This trial checks if a new tool can help doctors spot sepsis early in children. If your child is under 18, had a blood culture, and received strong antibiotics within the first day in the hospital, they may qualify.
This study looks at a specific blood protein level in children from birth to age 17. It compares healthy children and those with sepsis to see if the protein changes during infection.
This trial tests a new biomarker (T6A) to detect bacterial infections in newborn babies. It aims to help doctors diagnose infections faster and more accurately.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.